Menu
Recruiting NCT05055830

Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)

— Observational Cardiac Disease Critically Ill Children, Adult

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care..
Who it may be relevant to
Registry conditions: Cardiac Disease, Critically Ill, Children, Adult. Basic parameters: 0 months — 20 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Clinically Integrated Opportunistic PK/PD Trial in Critically Ill Children

Overview

OPTIC is a prospective, open-label, non-randomized study of multiple medications administered to approximately 2000 children in the pediatric cardiac intensive care unit (PCICU) per routine clinical car by their treating provider. The purpose of this study is to characterize the PK of drugs routinely administered to children per standard of care using opportunistic and scavenged samples. The prescribing of drugs to children will not be part of this protocol. After the child/adult (\<21 years of age) is consented/enrolled, demographic and clinical data will be extracted from the EHR. Biospecimen information (including date and time of sample collection) will be collected. Data analysis will be conducted on all participants with at least 2 evaluable samples. The protocol represents minimal risk to the children/adults who provide body fluid for this study, including potential loss of confidentiality (samples will be assigned a unique accession number) and risks associated with blood draws. Adverse Events (AEs)/Serious Adverse Events (SAEs) caused by the study specimen collections will be monitored and recorded in the Electronic Data Capture (EDC) system.

Interventions

  • Drug The OPTIC study is collecting PK data on children prescribed understudied drugs of interest per standard of care.
    The goal of this study is to characterize the pharmacokinetics of understudied drugs for which specific dosing recommendations and safety data are lacking. The prescribing of drugs to children will not be part of this protocol. Taking advantage of procedures done as part of routine medical care (i.e. blood draws), this study will serve as a tool to better understand drug exposure in children receiving these drugs per standard of care.

Primary outcome measures

  • Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling [Time frame: Data will be collected up to 180 days from the time of consent]
  • Half-life (t1/2) as measured by PK sampling [Time frame: Data will be collected up to 180 days from the time of consent]
  • Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling [Time frame: Data will be collected up to 180 days from the time of consent]
  • AUC (area under the curve) as measured by PK sampling [Time frame: Data will be collected up to 180 days from the time of consent]

Eligibility criteria

Inclusion criteria

To be eligible for enrollment, a potential participant must meet all the following criteria:

  • Participant is <21 years old on admission
  • Participant is admitted to the Pediatric Cardiac Intensive Care Unit
  • Parent/legal guardian/adult participant can understand the consent process and is willing to provide informed consent/assent
  • Participant is receiving one or more of the study drugs of interest at the time of enrollment

Exclusion criteria

1\. Any condition which would make the participant, in the opinion of the investigator, unsuitable for the study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

United States · 1 center
  • Duke University Medical Center — Durham

Publications

  • Thompson EJ, Foote HP, Hill KD, Hornik CP. A point-of-care pharmacokinetic/pharmacodynamic trial in critically ill children: Study design and feasibility. Contemp Clin Trials Commun. 2023 Jul 7;35:101182. doi: 10.1016/j.conctc.2023.101182. eCollection 2023 Oct. PMID 37485397

Identifiers

NCT: NCT05055830 · Pro00108566

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗